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Background: We aimed to evaluate the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein 
IIb/IIIa inhibitor (GPI) on early bleeding and ischemic events in non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients undergoing 
percutaneous coronary intervention (PCI).
methods: In TRACER, 12,944 NSTE ACS patients were randomized to vorapaxar or placebo. Administration of GPI was allowed at the treating 
physician’s discretion. We investigated whether use of GPI modified vorapaxar’s effect on the occurrence of non-coronary artery bypass grafting-
related bleeding at 7 days and ischemic events at 30 days. Cox proportional hazards modelling was used to calculate the hazard ratio (HR) adjusted 
for potential confounders.
results: 7,455 patients underwent PCI during index hospitalization. Of these, 2,023 (27.1%) patients received GPI prior to PCI start and 5,432 
(72.9%) did not. GPI use was higher in North America, and patients who received GPI were younger, had less chronic kidney disease, and were more 
often male. At 7 days, the rates of TIMI clinically significant bleeding were overall higher in patients who received GPI compared with those who did 
not (10.1% vs 5.5%). Vorapaxar was associated with increased bleeding in those who received GPI (11.0% vs 9.2%) and in those who did not (6.0% 
vs 4.9%). Both GPI (adjusted HR 1.97; 95% CI 1.63-2.39) and vorapaxar (adjusted HR 1.24; 95% CI 1.04-1.49) were independently associated 
with risk of bleeding without significant interaction (p-interaction=0.92). Similar trends were observed for GUSTO moderate or severe bleeding 
(p-interaction=0.16). At 30 days, cardiovascular death, myocardial infarction, or stroke rates with GPI were 9.1% in the vorapaxar group and 8.7% in 
the placebo group; without GPI, rates were 5.6% with vorapaxar and 6.5% with placebo (p-interaction=0.25).
conclusion: GPI use in NSTE ACS patients undergoing PCI was frequent but did not appear to interact with the efficacy or safety of vorapaxar. 
Nonetheless, GPI and vorapaxar were independently associated with increased risk of bleeding, and their combined use may result in additive effects 
on bleeding rates.
